HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $21
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $20 to $21.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 574 stocks hit new 52-week lows.
Morgan Stanley Downgrades ADC Therapeutics to Equal-Weight, Lowers Price Target to $11
Morgan Stanley analyst Matthew Harrison downgrades ADC Therapeutics (NYSE:ADCT) from Overweight to Equal-Weight and lowers the price target from $17 to $11.
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $29
RBC Capital analyst Gregory Renza maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target from $30 to $29.
ADC Therapeutics Q2 EPS $(0.73) Beats $(0.91) Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.91) by 19.78 percent. This is a 4.29 percent decrease over losses of $(0.70) per share from the
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Why ADC Therapeutics Shares Are Rising Today
ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the development and commercialization of ZYNLONTA.